TRDA Graph | ENTRADA THERAPEUTICS, INC.

TRDA Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $898.00K; Research and development $35.37M; Operating expenses $45.86M; Income tax $35.00K.
2026-03-31: Revenue $875.00K; Research and development $33.05M; Operating expenses $43.18M; Income tax $38.00K.
2025-12-31: Revenue $1.30M*; Research and development $33.96M*; Operating expenses $43.51M*; Income tax $92.00K*.
2025-09-30: Revenue $1.61M; Research and development $38.36M; Operating expenses $48.66M; Income tax $654.00K.

Counterparty Name

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$898.00K	$35.37M	$45.86M	$35.00K	-$42.76M
2026-03-31	$875.00K	$33.05M	$43.18M	$38.00K	-$39.72M
2025-12-31	$1.30M*	$33.96M*	$43.51M*	$92.00K*	-$39.16M*
2025-09-30	$1.61M	$38.36M	$48.66M	$654.00K	-$44.13M
2025-06-30	$1.95M	$37.88M	$48.80M	$178.00K	-$43.10M
2025-03-31	$20.56M	$32.07M	$42.35M	$0.00	-$17.35M
2024-09-30	$19.57M	$31.26M	$41.23M	-$1.86M	-$14.03M
2024-06-30	$94.69M	$32.03M	$41.27M	$2.76M	$55.03M
2024-03-31	$59.12M	$28.61M	$38.01M	$1.83M	$23.50M
2023-09-30	$43.73M	$22.19M	$29.72M	-$17.40M	$35.46M
2023-06-30	$18.17M	$26.30M	$34.47M	$13.85M	-$25.93M
2023-03-31	$25.26M	$23.10M	$31.04M	$3.55M	-$6.67M
2022-09-30	$0.00	$18.96M	$25.94M	$0.00	-$25.14M
2022-06-30	$0.00	$16.25M	$23.58M	$0.00	-$23.18M
2022-03-31	$0.00	$15.72M	$22.15M	$0.00	-$21.67M
2021-09-30	(m)	$10.51M	$14.36M	(m)	-$14.43M
2021-06-30	(m)	$6.83M	$9.91M	(m)	-$9.90M
2021-03-31	(m)	$6.22M	$8.39M	(m)	-$8.38M
2020-09-30	(m)	$5.70M	$6.97M	(m)	-$6.99M
2020-06-30	(m)	(m)	(m)	(m)	-$6.17M
2020-03-31	(m)	(m)	(m)	(m)	-$4.69M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$1.77M	$68.42M	$89.04M	$73.00K	-$82.48M
2025-06-30	$22.51M	$69.95M	$91.15M	$178.00K	-$60.45M
2024-06-30	$153.81M	$60.64M	$79.28M	$4.59M	$78.53M
2023-06-30	$43.43M	$49.40M	$65.51M	$17.40M	-$32.60M
2022-06-30	$0.00	$31.97M	$45.73M	$0.00	-$44.85M
2021-06-30	(m)	$13.05M	$18.30M	(m)	-$18.28M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$24.12M	$108.31M	$139.81M	$832.00K	-$104.59M
2024-09-30	$173.38M	$91.90M	$120.51M	$2.73M	$64.50M
2023-09-30	$87.17M	$71.59M	$95.23M	$0.00	$2.86M
2022-09-30	$0.00	$50.92M	$71.67M	$0.00	-$69.99M
2021-09-30	(m)	$23.56M	$32.67M	(m)	-$32.71M
2020-09-30	(m)	$14.45M	$18.01M	(m)	-$17.85M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$25.42M	$142.27M	$183.32M	$924.00K	-$143.75M
2024-12-31	$210.78M	$125.31M	$163.77M	$859.00K	$65.63M
2023-12-31	$129.01M	$99.88M	$132.18M	$18.74M	-$6.68M
2022-12-31	(m)	$66.61M	$97.25M	$0.00	-$94.62M
2021-12-31	(m)	$35.93M	$51.13M	$0.00	-$51.16M
2020-12-31	(m)	$21.10M	$26.67M	$0.00	-$26.52M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Cue Biopharma, Inc. (CUE)	United States	$0.243B	-1.01
MACROGENICS INC (MGNX)	United States	$0.242B	-20.11
Pyxis Oncology, Inc. (PYXS)	United States	$0.244B
Camp4 Therapeutics Corp (CAMP)	United States	$0.240B	-2.12
Lyell Immunopharma, Inc. (LYEL)	United States	$0.248B	-1.32
Sionna Therapeutics, Inc. (SION)	United States	$0.236B	-20.37
SIGA TECHNOLOGIES INC (SIGA)	United States	$0.234B	-93.33
Cartesian Therapeutics, Inc. (RNAC)	United States	$0.231B	-2.04
Akebia Therapeutics, Inc. (AKBA)	United States	$0.255B	-10.35
Keros Therapeutics, Inc. (KROS)	United States	$0.229B	-2.55